Allarity Therapeutics Presents Phase 2 Stenoparib Trial Poster at ESMO
Allarity Therapeutics announced the presentation of a Trial-in-Progress poster for its Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026. The poster outlines the scientific background, study design, and clinical rationale for evaluating stenoparib, a dual PARP and WNT pathway inhibitor, in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer. The company emphasized this as an important opportunity to highlight the clinical rationale and design of the study to a specialized audience.
Key Highlights
- Allarity Therapeutics presented a Trial-in-Progress poster at ESMO Gynaecological Cancers Congress 2026.
- The poster detailed the Phase 2 trial of stenoparib for advanced ovarian cancer.
- Stenoparib is a dual PARP and WNT pathway inhibitor.
- The trial targets platinum-resistant or platinum-ineligible ovarian cancer patients.
- Principal Investigator Kathleen N. Moore, M.D., presented the poster.
- The presentation focused on study design and clinical rationale, not new clinical data.
- The company utilizes its DRP® companion diagnostic for patient selection.
Price Impact
More from ALLR
Allarity to Present Stenoparib Phase 2 Ovarian Cancer Trial Poster at ESMO
Allarity Therapeutics Amends CEO Management Services Agreement
Allarity Therapeutics Q1 Net Loss $(2.75)M; Secures $20M in Promissory Notes